DNM1L and breast carcinoma: Depleting or pharmacologically inhibiting DRP1 in preclinical breast cancer metastasis models disrupts mitochondrial dynamics, cellular bioenergetics and redox homeostasis, resulting in attenuated brain metastasis (Fig. 7).